While low doses of PPR have been associated with neuroprotective effects, such as enhanced cognitive function and prevention of oxidative stress in the brain, high doses have been shown to impair cognitive performance and dampen long-term potentiation (69)
PLoS ONE 9:e93846
Metabolism & Elimination GLP2 undergoes metabolism through pathways typical of peptide therapeutics: Plasma half-life of approximately 5 days in humans, enabling once-weekly administration Primary metabolic pathways include proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis Not metabolized via cytochrome P450 enzymes, sulfation, or glucuronidation pathways Low potential for drug-drug interactions mediated through hepatic metabolism or transporter systems The extended half-life represents a key pharmacokinetic advantage, with steady-state accumulation of approximately 1.7-fold enabling consistent therapeutic exposure throughout the dosing interval
doi: 10.1016/S0140-6736(08)60694-7 47 GrysiewiczRAThomasKPandeyDK
(1994 Madhre, S
Online sellers may advertise products as research only, not for human use, or laboratory use, which is a red flag for patients